Compass Therapeutics (CMPX) EBITDA (2023 - 2025)
Historic EBITDA for Compass Therapeutics (CMPX) over the last 3 years, with Q3 2025 value amounting to -$14.2 million.
- Compass Therapeutics' EBITDA fell 4330.57% to -$14.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$66.0 million, marking a year-over-year decrease of 4093.46%. This contributed to the annual value of -$49.2 million for FY2024, which is 1671.69% down from last year.
- As of Q3 2025, Compass Therapeutics' EBITDA stood at -$14.2 million, which was down 4330.57% from -$19.9 million recorded in Q2 2025.
- In the past 5 years, Compass Therapeutics' EBITDA ranged from a high of -$7.7 million in Q1 2023 and a low of -$19.9 million during Q2 2025
- Moreover, its 3-year median value for EBITDA was -$12.9 million (2023), whereas its average is -$12.9 million.
- As far as peak fluctuations go, Compass Therapeutics' EBITDA fell by 17.19% in 2024, and later plummeted by 5258.38% in 2025.
- Over the past 3 years, Compass Therapeutics' EBITDA (Quarter) stood at -$12.9 million in 2023, then decreased by 18.23% to -$15.3 million in 2024, then grew by 7.29% to -$14.2 million in 2025.
- Its EBITDA stands at -$14.2 million for Q3 2025, versus -$19.9 million for Q2 2025 and -$16.7 million for Q1 2025.